MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
Outlook Therapeutics Interest Expense 2011-2026 | OTLK
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Outlook Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -1.49 M | -936 K | 1.76 M | 3.47 M | 3.89 M | 5.63 M | 1.47 M | 2.3 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.63 M | -1.49 M | 2.01 M |
Quarterly Interest Expense Outlook Therapeutics
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -49.4 K | -18.5 K | 48.9 K | - | 405 K | -3.08 M | 189 K | - | 303 | 188 K | -2.45 M | -1.13 M | -357 K | -418 K | -352 K | -667 K | -257 K | 250 K | 160 K | -1.74 M | 444 K | 696 K | 598 K | 3.26 M | 1.08 M | 598 K | 1.12 M | 2.79 M | 1.15 M | 1.12 M | 718 K | 3.48 M | 1.75 M | 718 K | 489 K | 1.24 M | 299 K | 387 K | 399 K | 1.62 M | 555 K | 706 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.48 M | -3.08 M | 398 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.83 | 2.56 % | $ 9.21 B |  Australia |
 |
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 327.37 | -1.81 % | $ 42.9 B | USA |
 |
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
722 K | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | USA |
 |
Cabaletta Bio
CABA
|
2 M | $ 3.48 | 2.39 % | $ 350 M | USA |
 |
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B |  France |
 |
Aligos Therapeutics
ALGS
|
2.2 M | $ 8.22 | 10.78 % | $ 81.3 M | USA |
 |
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | USA |
 |
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 21.55 | -0.6 % | $ 1.01 B | USA |
 |
CymaBay Therapeutics
CBAY
|
18.9 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
14.2 M | $ 100.72 | 1.25 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 3.1 | -2.21 % | $ 5.1 M |  Israel |
 |
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
-4.81 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
58 K | $ 1.42 | -8.71 % | $ 365 M | USA |
 |
Galectin Therapeutics
GALT
|
1.03 M | $ 2.39 | -6.65 % | $ 153 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.18 | -1.3 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
443 K | $ 24.21 | -1.53 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.52 | 1.68 % | $ 405 M |  Britain |
 |
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-257 K | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
927 K | $ 33.67 | -0.61 % | $ 2.24 B | USA |
 |
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | USA |